Urology
Volume 75, Issue 5 , Pages 1009-1014 , May 2010

Cryoimmunotherapy in Urologic Oncology

  • Abhinav Sidana

      Affiliations

    • James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Wasim H. Chowdhury

      Affiliations

    • James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Ephraim J. Fuchs

      Affiliations

    • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Ronald Rodriguez

      Affiliations

    • James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: Ronald Rodriguez, M.D., Ph.D., James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Marburg Room 205, 600 N Wolfe St, Baltimore, MD 21287-2101

Received 14 May 2009 ,Accepted 10 June 2009.

References 

  1. Korpan NN. A history of cryosurgery: its development and future. J Am Coll Surg. 2007;204:314–324
  2. Arnott J. Practical illustrations of the remedial efficacy of a very low or anaesthetic temperature. Lancet. 1850;2:257–259
  3. Campbell-White A. Liquid air: its application in medicine and surgery. Med Rec. 1899;56:109–112
  4. Campbell-White A. Possibilities of liquid air to the physician. J Am Med Assoc. 1901;36:1354–1356
  5. Cooper IS, Lee AS. Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis. 1961;133:259–263
  6. Cooper IS. Cryogenic surgery (A new method of destruction or extirpation of benign or malignant tissues). N Engl J Med. 1963;268:743–749
  7. Cooper IS. Cryogenic surgery of the basal ganglia. J Am Med Assoc. 1962;181:600–604
  8. Das K, Benzil DL, Rovit RL, et al. Irving S Cooper; 1922-85: a pioneer in functional neurosurgery. J Neurosurg. 1998;89:865–873
  9. Gonder MJ, Soanes WA, Smith V. Chemical and morphologic changes in the prostate following extreme cooling. Ann NY Acad Sci. 1965;125:716–729
  10. Gonder MJ, Soanes WA, Smith V. Experimental prostate cryosurgery. Invest Urol. 1964;1:610–619
  11. Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Invest Urol. 1966;3:372–378
  12. Zacarian SA, Adham MI. Cryotherapy of cutaneous malignancy. Cryobiology. 1966;2:212–218
  13. Crisp WE, Asadourian L, Romberger W. Application of cryosurgery to gynecologic malignancy. Obstet Gynecol. 1967;30:668–673
  14. Pandey SK, Milverton EJ, Maloof AJ. A tribute to Charles David Kelman MD: ophthalmologist, inventor and pioneer of phacoemulsification surgery. Clin Experiment Ophthalmol. 2004;32:529–533
  15. Korpan NN. Hepatic cryosurgery for liver metastases (Long-term follow-up). Ann Surg. 1997;225:193–201
  16. Korpan NN. Basics of Cryosurgery. New York, Veinna, Sydney, Munich: Springer; 2001;
  17. Onik G, Porterfield B, Rubinsky B, et al. Percutaneous transperineal prostate cryosurgery using transrectal ultrasound guidance: animal model. Urology. 1991;37:277–281
  18. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291–1299
  19. Ritch CR, Katz AE. Prostate cryotherapy: current status. Curr Opin Urol. 2009;19:177–181
  20. Jones JS, Rewcastle JC, Donnelly BJ, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:554–558
  21. Pisters LL, Rewcastle JC, Donnelly BJ, et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:559–564
  22. Sindelar WF, Javadpour N, Bagley DH. Histological and ultrastructural changes in rat kidney after cryosurgery. J Surg Oncol. 1981;18:363–379
  23. Uchida M, Imaide Y, Sugimoto K, et al. Percutaneous cryosurgery for renal tumours. Br J Urol. 1995;75:132–137
  24. Hafron J, Kaouk JH. Cryosurgical ablation of renal cell carcinoma. Cancer Control. 2007;14:211–217
  25. Karlsson JO, Cravalho EG, Borel Rinkes IH, et al. Nucleation and growth of ice crystals inside cultured hepatocytes during freezing in the presence of dimethyl sulfoxide. Biophys J. 1993;65:2524–2536
  26. Fraser J, Gill W. Observations on ultra-frozen tissue. Br J Surg. 1967;54:770–776
  27. Whittaker DK. Mechanisms of tissue destruction following cryosurgery. Ann R Coll Surg Engl. 1984;66:313–318
  28. Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60:40–49
  29. Yantorno C, Soanes WA, Gonder MJ, et al. Studies in cryo-immunology. I (The production of antibodies to urogenital tissue in consequence of freezing treatment). Immunology. 1967;12:395–410
  30. Shulman S, Brandt EJ, Yantorno C. Studies in cryo-immunology. II (Tissue and species specificity of the autoantibody response and comparison with iso-immunization). Immunology. 1968;14:149–158
  31. Blackwood J, Moore FT, Pace WG. Cryotherapy for malignant tumors. Cryobiology. 1967;4:33–38
  32. Moore FT, Blackwood J, Sanzenbacher L, et al. Cryotherapy for malignant tumors (Immunologic response). Arch Surg. 1968;96:527–529
  33. Ablin RJ. Cryoimmunotherapy. Br Med J. 1972;3:476
  34. Soanes WA, Gonder MJ, Ablin RJ. A possible immuno-cryothermic response in prostatic cancer. Clin Radiol. 1970;21:253–255
  35. Blackwood CE, Cooper IS. Response of experimental tumor systems to cryosurgery. Cryobiology. 1972;9:508–515
  36. Neel HB, Ketcham AS, Hammond WG. Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope. 1973;83:376–387
  37. Bagley DH, Faraci RP, Marrone JC, et al. Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res. 1974;17:404–406
  38. Matsumura K, Sakata K, Saji S, et al. Antitumor immunologic reactivity in the relatively early period after cryosurgery: experimental studies in the rat. Cryobiology. 1982;19:263–272
  39. Misao A, Sakata K, Saji S, et al. Late appearance of resistance to tumor rechallenge following cryosurgery (A study in an experimental mammary tumor of the rat). Cryobiology. 1981;18:386–389
  40. Lubaroff DM, Reynolds CW, Canfield L, et al. Immunologic aspects of the prostate. Prostate. 1981;2:233–248
  41. Joosten JJ, Muijen GN, Wobbes T, et al. In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology. 2001;42:49–58
  42. Sabel MS, Nehs MA, Su G, et al. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90:97–104
  43. Allen PJ, D'Angelica M, Hodyl C, et al. The effects of hepatic cryosurgery on tumor growth in the liver. J Surg Res. 1998;77:132–136
  44. Zonnevylle JA, Zwaveling A. The influence of cryosurgery and electrocoagulation upon metastatic spread. J Surg Oncol. 1984;27:131–134
  45. Hoffmann NE, Coad JE, Huot CS, et al. Investigation of the mechanism and the effect of cryoimmunology in the Copenhagen rat. Cryobiology. 2001;42:59–68
  46. Hayakawa K, Yamashita T, Suzuki K, et al. Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholanthrene-induced primary autochthonous tumors. Gann. 1982;73:462–469
  47. Yamashita T, Hayakawa K, Hosokawa M, et al. Enhanced tumor metastases in rats following cryosurgery of primary tumor. Gann. 1982;73:222–228
  48. Wing MG, Goepel JR, Jacob G, et al. Comparison of excision versus cryosurgery of an HSV-2-induced fibrosarcoma. I (Survival, extent of metastatic disease and host immunocompetence following surgery). Cancer Immunol Immunother. 1988;26:161–168
  49. Friedman EJ, Orth CR, Brewton KA, et al. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from dunning prostatic adenocarcinoma challenge. J Urol. 1997;158:1585–1588
  50. Steinman RM. Some interfaces of dendritic cell biology. APMIS. 2003;111:675–697
  51. den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95:896–905
  52. Tanaka S. Immunological aspects of cryosurgery in general surgery. Cryobiology. 1982;19:247–262
  53. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003;170:S84–S89
  54. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22
  55. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor—secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883–3891
  56. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol. 2006;24:419–424
  57. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537–1546
  58. Chagnon F, Tanguay S, Ozdal OL, et al. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res. 2005;11:1302–1311
  59. Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev. 2009;61:268–274
  60. den Brok MH, Sutmuller RP, Nierkens S, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 2006;66:7285–7292
  61. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19:217–223
  62. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912
  63. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4+ CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res. 2008;14:1032–1040
  64. Golgher D, Jones E, Powrie F, et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol. 2002;32:3267–3275
  65. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59:3128–3133
  66. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol. 2008;28:109–126
  67. Salem ML, Kadima AN, El-Naggar SA, et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007;30:40–53
  68. Levy MY, Sidana A, Chowdhury WH, et al. Cyclophosphamide unmasks an anti-metastatic effect of local tumor cryoablation. J Pharmacol Exp Ther, in press.
  69. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339
  70. Eagar TN, Karandikar NJ, Bluestone JA, et al. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol. 2002;32:972–981
  71. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–2627
  72. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006;24:442–447
  73. Yang JC, Beck KE, Blansfield JA, et al. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (mdx-010). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005, vol. 23.
  74. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer. 2006;5:206–211
  75. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757–1761
  76. Li B, Van RM, Wang C, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor—secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15:1623–1634
  77. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293–12297

PII: S0090-4295(09)00845-0

doi: 10.1016/j.urology.2009.06.020

Urology
Volume 75, Issue 5 , Pages 1009-1014 , May 2010

Article Tools